No Data
Express News | HC Wainwright & Co. Reiterates Buy on ATAI Life Sciences, Maintains $15 Price Target
ATAI Life Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/17/2024 702.14% HC Wainwright & Co. → $15 Reiterates Buy → Buy 04/04/2024 — Cantor Fitzgerald Reiterat
Buy Rating Affirmed for ATAI Life Sciences Amid Promising TRD Treatment Developments and Strategic Growth Potential
Buy Recommendation for ATAI Life Sciences Amidst Cost-Optimization and Promising Clinical Milestones
Atai Life Sciences Poised to Create Value as Psychedelic Therapies Gain Traction, Analysts Believe | NASDAQ:ATAI, ETR:9VC
Analysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA), Celcuity (CELC) and ATAI Life Sciences (ATAI)